Wedbush reiterates Outperform on Damora Therapeutics
Wedbush analyst David Nierengarten reaffirmed an Outperform rating for Damora Therapeutics, maintaining a price target of $35. The rating covers the NASDAQ-listed stock under ticker DMRA.

*this image is generated using AI for illustrative purposes only.
Wedbush analyst David Nierengarten has reaffirmed an Outperform rating for Damora Therapeutics, maintaining a price target of $35. The rating applies to the company listed on NASDAQ under the ticker DMRA.
The reiteration underscores the analyst's continued confidence in the stock's performance potential. No specific changes to the financial outlook or operational metrics were detailed in the update.
What upcoming catalysts or milestones could drive Damora Therapeutics toward the $35 price target?
How might broader market conditions affect the stock's ability to reach the projected target?
Are there any anticipated changes in Damora's pipeline or partnerships that could influence future performance?

























